Founded in 1985 in Toulouse, HEMODIA has established itself as a key player in the medical device industry, particularly through the production of single-use care sets for dialysis, infusion, oncology, and intensive care. The Group has also expanded its activities into arthroscopy by developing a range of pumps and tubing specifically designed for minimally invasive surgical procedures. HEMODIA employs 500 people and operates five production facilities both in France and internationally, generating a revenue of €50 million. HEMODIA leverages top-notch industrial capabilities and recognized expertise to provide high-quality solutions to healthcare institutions in France and around the world.
With support from BPI FRANCE and MULTICROISSANCE, the investment fund LBO FRANCE has acquired a majority stake in HEMODIA, along with a minority investment from AFRICINVEST. This operation has allowed Rémi Teulière, the President of the Group, to reinvest and will enable him to drive the Group's strategic project alongside its new financial shareholders. This restructuring of the capital allowed for the exit of founder Pierre Montoriol and IXO Private Equity, which had joined the capital in 2019.
This new LBO initiative aims to boost the Group's growth by leveraging two strategic areas. First, HEMODIA plans to strengthen its core business of single-use care sets through a targeted international expansion strategy. Already a leader in France with significant market shares, the Group now aims to establish a lasting presence in Europe. Second, HEMODIA intends to accelerate the development of its rapidly growing arthroscopy segment. The Group seeks to solidify its position in this market by focusing on a strong innovation drive, launching new high-value products.
With the support of its new majority shareholder, HEMODIA is positioning itself to reach new heights by leveraging its historical strengths and benefiting from strategic and financial guidance.
Customer review on this operation